AUDUBON, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ADIRA™ XLIF™ Plate System, the Company's first product launch compatible across its expanded lateral interbody portfolio. "This launch represents an important milestone in our integration roadmap," said David Hole, president of Spine at Globus Medical. "Through the system's ability to be paired with our industry-leading Globus and NuVasi ...

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED) on behalf of Globus stockholders. Our investigation concerns whether Globus has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 13, 2024, in a filing with the U.S. Securities and Exchange Co ...

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE: GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED. Investigation Details On August 13, 2024, in a filing with the U.S. Securities and Exchange Commission, Gl ...

Globus Medical, Inc. (GMED) reported second-quarter 2024 adjusted earnings per share (EPS) of 75 cents, which beat the Zacks Consensus Estimate by 10.3%. The figure increased 19% year over year. The adjusted EPS excludes certain non-recurring expenses and benefits, such as the amortization of intangibles, merger and acquisition-related costs/licensing and provision for litigation, among others. Without adjustments, the company registered a GAAP diluted EPS of 23 cents, down 59.6% from the year-ago quarter's ...

Globus Medical (GMED) reported $629.69 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 115.9%. EPS of $0.75 for the same period compares to $0.63 a year ago. The reported revenue represents a surprise of +2.39% over the Zacks Consensus Estimate of $615 million. With the consensus EPS estimate being $0.68, the EPS surprise was +10.29%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...

Globus Medical (GMED) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.29%. A quarter ago, it was expected that this medical device company would post earnings of $0.55 per share when it actually produced earnings of $0.72, delivering a surprise of 30.91%. Over the last four quarte ...

AUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. Worldwide net sales were $629.7 million, an increase of 115.9% or 117.3% on a constant currency basis GAAP net income for the quarter was $31.8 million GAAP diluted earnings per share ("EPS") was $0.23 and non-GAAP diluted EPS was $0.75 Non-GAAP adjusted EBITDA was $190.4 million, or 30.2% of net sales "I'm ...

Globus Medical is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures. In line with the company's business strategy to focus on its integrated product development, Globus Medical is consistently making efforts in research and development. Per the company, its team-oriented approach, active surgeon input and ...

Core Viewpoint - Globus Medical, Inc. has received FDA 510(k) clearance for its new robotic navigation platform, ExcelsiusFlex™, designed for Total Knee Arthroplasty (TKA), along with the ACTIFY™ 3D Total Knee System, enhancing surgical precision and efficiency in orthopedic procedures [3][6]. Product Developments - ExcelsiusFlex™ is engineered to assist surgeons in primary total knee arthroplasty with robotically guided resections, offering multiple workflows and unrestricted jig-less resections [4]. - The ACTIFY™ 3D Total Knee System is designed for cementless reconstruction, combining strength with a porous lattice interface for effective fixation, and provides a comprehensive suite of implants and instruments [5][11]. Market Positioning - The introduction of ExcelsiusFlex™ and ACTIFY™ 3D aims to provide next-generation robotic and implant technology to the orthopedic market, enhancing precision, efficiency, and flexibility for surgeons [6]. - With the FDA clearances, Globus Medical is preparing for commercial release and ramping up production of these innovative systems [6]. Indications for Use - ExcelsiusFlex™ is intended to aid in the precise location of anatomical structures and assist in planning the position of implant components during orthopedic procedures [7][9]. - The compatible TKA implant systems with ExcelsiusFlex™ include GENflex2™ and ACTIFY™ Total Knee System, which are indicated for various conditions including osteoarthritis and post-traumatic degenerative problems [8][11]. Company Overview - Globus Medical is a leading musculoskeletal company focused on developing technologies and products that address unmet clinical needs and promote patient healing [12].

Safe Harbor Statements All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan" and other similar terms. These forwardlooking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and ...